L
Lineage Cell Therapeutics Inc (LCTX)
Official siteHEALTHCARE • BIOTECHNOLOGY • AMEX
$0.80
-0.11 (-12.45%)
Market Cap: $231.35M
Last updated: Nov 17, 2026 at 11:06 AM ET
Lineage Cell Therapeutics Inc (LCTX) Valuation Multiples
Lineage Cell Therapeutics (LCTX) trades at 18.7x sales and 3.0x book value. Its P/S of 18.7x is below its 5-year median of 20.5x. Its forward P/E is 30.7x.
Current Multiples
| Multiple | Value |
|---|---|
| P/E (trailing) | N/A |
| Forward P/E | 30.7x |
| Price to sales | 18.7x |
| Price to book | 3.0x |
| PEG | N/A |
| FCF yield | -13.1% |
Historical Medians
Against its 10-year medians, its P/S is 18.7% below 23.0x and its P/B is 11.1% above 2.7x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 18.7x | 20.5x | 23.0x |
| P/B | 3.0x | 3.1x | 2.7x |
Valuation History
Over the 10 year ends shown, its P/S ranged from 0.7x in 2020 to 72.6x in 2017.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $1.67 | N/A | 26.3x | 8.6x |
| 2024 | $0.50 | N/A | 10.1x | 1.3x |
| 2023 | $1.09 | N/A | 20.9x | 3.0x |
| 2022 | $1.17 | N/A | 13.5x | 2.7x |
| 2021 | $2.45 | N/A | 1.0x | 4.5x |
| 2020 | $1.76 | N/A | 0.7x | 2.7x |
| 2019 | $0.89 | N/A | 36.7x | 1.2x |
| 2018 | $0.91 | N/A | 23.2x | 1.2x |
| 2017 | $2.15 | N/A | 72.6x | 1.7x |
| 2016 | $3.61 | 11.3x | 58.6x | 3.1x |
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About LCTX
What is LCTX's forward P/E ratio?
Lineage Cell Therapeutics has a forward P/E ratio of 30.7x.
Is LCTX stock overvalued?
GNG's valuation label for LCTX is Fairly valued.
What is LCTX's price to sales ratio?
Lineage Cell Therapeutics has a price to sales ratio of 18.7x.
LCTX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors